Cutaneous HPV23 E6 prevents p53 phosphorylation through interaction with HIPK2

PLoS ONE

Volumn 6, Issue 11, 2011, Pages

  Muschik, Dorothea ^a   Braspenning Wesch, Ilona ^a   Stockfleth, Eggert ^b   Rösl, Frank ^a   Hofmann, Thomas G ^c   Nindl, Ingo ^a,b  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c GERMAN CANCER RESEARCH CENTER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

HOMEODOMAIN INTERACTING PROTEIN KINASE 2; PROTEIN E6; PROTEIN P53; CARRIER PROTEIN; HIPK2 PROTEIN, HUMAN; ONCOPROTEIN; PROTEIN SERINE THREONINE KINASE; SERINE;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL DAMAGE; CELL NUCLEUS INCLUSION BODY; COMPLEX FORMATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 23; IN VITRO STUDY; IN VIVO STUDY; KERATINOCYTE; NONHUMAN; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; SKIN CARCINOGENESIS; ULTRAVIOLET B RADIATION; WART VIRUS; ACTIVE TRANSPORT; CELL NUCLEUS; CHEMISTRY; CYTOLOGY; DNA DAMAGE; METABOLISM; PAPILLOMA VIRUS; PHOSPHORYLATION; PROTEIN TRANSPORT; RADIATION EXPOSURE; SKIN; TUMOR CELL LINE; ULTRAVIOLET RADIATION; VIROLOGY;

PAPILLOMAVIRIDAE;

ACTIVE TRANSPORT, CELL NUCLEUS; APOPTOSIS; CARRIER PROTEINS; CELL LINE, TUMOR; CELL NUCLEUS; DNA DAMAGE; HUMANS; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRIDAE; PHOSPHORYLATION; PROTEIN TRANSPORT; PROTEIN-SERINE-THREONINE KINASES; SERINE; SKIN; TUMOR SUPPRESSOR PROTEIN P53; ULTRAVIOLET RAYS;

EID: 81155128349     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0027655     Document Type: Article

References (37)

1. Bernard HU, Burk RD, Chen Z, van Doorslaer K, zur Hausen H, et al. (2010) Classification of papillomaviruses (PVs) based on 189 PV types and proposal of taxonomic amendments. Virology 401: 70-79.
2. Kohler A, Gottschling M, Manning K, Lehmann MD, Schulz E, et al. (2011) Genomic characterization of ten novel cutaneous human papillomaviruses from keratotic lesions of immunosuppressed patients. J Gen Virol 92: 1585-1594.
3. de Villiers EM, Fauquet C, Broker TR, Bernard HU, zur Hausen H, (2004) Classification of papillomaviruses. Virology 324: 17-27.
4. Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, et al. (2003) Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 348: 518-527.
5. International Agency for Research on Cancer (1995) IARC monographs on the evaluation of carcinogenic risks to humans. Human papillomaviruses. IARC Lyon France 64.
6. zur Hausen H, (2006) Infections causing human cancer. Weinheim, Germany WILEY_VCH Verlag GmbH & Co. KGaA.
7. zur Hausen H, (2002) Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer 2: 342-350.
8. Huibregtse JM, Scheffner M, Howley PM, (1993) Localization of the E6-AP regions that direct human papillomavirus E6 binding, association with p53, and ubiquitination of associated proteins. Mol Cell Biol 13: 4918-4927.
9. Huibregtse JM, Scheffner M, Beaudenon S, Howley PM, (1995) A family of proteins structurally and functionally related to the E6-AP ubiquitin-protein ligase. Proc Natl Acad Sci USA 92: 5249.
10. Jablonska S, Dabrowski J, Jakubowicz K, (1972) Epidermodysplasia verruciformis as a model in studies on the role of papovaviruses in oncogenesis. Cancer Res 32: 583-589.
11. Orth G, Jablonska S, Favre M, Croissant O, Jarzabek-Chorzelska M, et al. (1978) Characterization of two types of human papillomaviruses in lesions of epidermodysplasia verruciformis. Proc Natl Acad Sci USA 75: 1537-1541.
12. Pfister H, (2003) Chapter 8: Human papillomavirus and skin cancer. J Natl Cancer Inst Monogr 52-56.
13. Akgül B, Cooke JC, Storey A, (2006) HPV-associated skin disease. J Pathol 208: 165-175.
14. Nindl I, Gottschling M, Stockfleth E, (2007) Human papillomaviruses and non-melanoma skin cancer: Basic virology and clinical manifestations. Dis Markers 23: 247-259.
15. Weissenborn SJ, Nindl I, Purdie K, Harwood C, Proby C, et al. (2005) Human papillomavirus-DNA loads in actinic keratoses exceed those in non-melanoma skin cancers. J Invest Dermatol 125: 93-97.
16. de Koning MN, Weissenborn SJ, Abeni D, Bouwes Bavinck JN, Euvrard S, et al. (2009) Prevalence and associated factors of betapapillomavirus infections in individuals without cutaneous squamous cell carcinoma. J Gen Virol 90: 1611-1621.
17. Bouwes Bavinck JN, Neale RE, Abeni D, Euvrard S, Green AC, et al. (2010) Multicenter study of the association between betapapillomavirus infection and cutaneous squamous cell carcinoma. Cancer Res 70: 9777-9786.
18. Proby CM, Harwood CA, Neale RE, Green AC, Euvrard S, et al. (2011) A Case-Control Study of Betapapillomavirus Infection and Cutaneous Squamous Cell Carcinoma in Organ Transplant Recipients. Am J Transplant 11: 1498-1508.
19. Caldeira S, Zehbe I, Accardi R, Malanchi I, Dong W, et al. (2003) The E6 and E7 proteins of the cutaneous human papillomavirus type 38 display transforming properties. J Virol 77: 2195-2206.
20. Jackson S, Harwood C, Thomas M, Banks L, Storey A, (2000) Role of Bak in UV-induced apoptosis in skin cancer and abrogation by HPV E6 proteins. Genes Dev 14: 3065-3073.
21. Jackson S, Storey A, (2000) E6 proteins from diverse cutaneous HPV types inhibit apoptosis in response to UV damage. Oncogene 19: 592-598.
22. Underbrink MP, Howie HL, Bedard KM, Koop JI, Galloway DA, (2008) E6 proteins from multiple human betapapillomavirus types degrade Bak and protect keratinocytes from apoptosis after UVB irradiation. J Virol 82: 10408-10417.
23. D'Orazi G, Cecchinelli B, Bruno T, Manni I, Higashimoto Y, et al. (2002) Homeodomain-interacting protein kinase-2 phosphorylates p53 at Ser 46 and mediates apoptosis. Nat Cell Biol 4: 11-19.
24. Hofmann TG, Moller A, Sirma H, Zentgraf H, Taya Y, et al. (2002) Regulation of p53 activity by its interaction with homeodomain-interacting protein kinase-2. Nat Cell Biol 4: 1-10.
25. Winter M, Sombroek D, Dauth I, Moehlenbrink J, Scheuermann K, et al. (2008) Control of HIPK2 stability by ubiquitin ligase Siah-1 and checkpoint kinases ATM and ATR. Nat Cell Biol 10: 812-824.
26. Oda K, Arakawa H, Tanaka T, Matsuda K, Tanikawa C, et al. (2000) p53AIP1, a potential mediator of p53-dependent apoptosis, and its regulation by Ser-46-phosphorylated p53. Cell 102: 849-862.
27. Sombroek D, Hofmann TG, (2009) How cells switch HIPK2 on and off. Cell Death Differ 16: 187-194.
28. Hofmann TG, Will H, (2003) Body language: the function of PML nuclear bodies in apoptosis regulation. Cell Death Differ 10: 1290-1299.
29. Wei G, Ku S, Ma GK, Saito S, Tang AA, et al. (2007) HIPK2 represses beta-catenin-mediated transcription, epidermal stem cell expansion, and skin tumorigenesis. Proc Natl Acad Sci USA 104: 13040-13045.
30. Sherman L, Schlegel R, (1996) Serum- and calcium-induced differentiation of human keratinocytes is inhibited by the E6 oncoprotein of human papillomavirus type 16. J Virol 70: 3269-3279.
31. Guccione E, Massimi P, Bernat A, Banks L, (2002) Comparative analysis of the intracellular location of the high- and low-risk human papillomavirus oncoproteins. Virology 293: 20-25.
32. Massimi P, Thomas M, Bouvard V, Ruberto I, Campo MS, et al. (2008) Comparative transforming potential of different human papillomaviruses associated with non-melanoma skin cancer. Virology 371: 374-379.
33. Dauth I, Kruger J, Hofmann TG, (2007) Homeodomain-interacting protein kinase 2 is the ionizing radiation-activated p53 serine 46 kinase and is regulated by ATM. Cancer Res 67: 2274-2279.
34. Heldin CH, Johnsson A, Wennergren S, Wernstedt C, Betsholtz C, et al. (1986) A human osteosarcoma cell line secretes a growth factor structurally related to a homodimer of PDGF A-chains. Nature 319: 511-514.
35. Hofmann TG, Jaffray E, Stollberg N, Hay RT, Will H, (2005) Regulation of homeodomain-interacting protein kinase 2 (HIPK2) effector function through dynamic small ubiquitin-related modifier-1 (SUMO-1) modification. J Biol Chem 280: 29224-29232.
36. Hofmann TG, Stollberg N, Schmitz ML, Will H, (2003) HIPK2 regulates transforming growth factor-beta-induced c-Jun NH(2)-terminal kinase activation and apoptosis in human hepatoma cells. Cancer Res 63: 8271-8277.
37. Schneider G, Saur D, Siveke JT, Fritsch R, Greten FR, et al. (2006) IKKalpha controls p52/RelB at the skp2 gene promoter to regulate G1- to S-phase progression. EMBO J 25: 3801-3812.